Jubilant Therapeutics

Jubilant Tx is a patient-focused biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology & autoimmune diseases.

[Jubilant Therapeutics @JubilantTx]

“Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology” in @BioSpace discusses our innovative pipeline targeting oncology & immunology, TIBEO discovery engine, & interest in strategic partnerships.

https://t.co/l6PytFxwhP

[Jubilant Therapeutics @JubilantTx]

Welcome our newest independent member of our Board of Directors, Mr. Nadir Patel. He has had a notable career in government affairs & advising corporate execs. We’re thrilled to have such a seasoned strategist assisting us as we progress our drug pipeline.
https://t.co/wb7cGJ6sdR

[Jubilant Therapeutics @JubilantTx]

We’re at @ASCO! Today is the first day of the Annual Meeting in Chicago and we are excited to network with our peers. Please reach out to us at [email protected] if you are attending and would like to discuss our research. #ASCO23

[Jubilant Therapeutics @JubilantTx]

Jubilant Therapeutics is attending @IAmBiotech International Convention next week in Boston. Our team is available for one-on-one meetings to discuss our pipeline and can be scheduled using the partnering link below or email [email protected]. #BIO23

https://t.co/LzRfU5Oo29

[Jubilant Therapeutics @JubilantTx]

Jubilant Therapeutics is attending @ASCO Annual Meeting in two weeks in Chicago. Various members of our team will be present and are eager to connect with fellow oncology innovators.

To connect in person, email [email protected].

[Jubilant Therapeutics @JubilantTx]

CEO, Syed Kazmi, Ph.D., is pleased to be attending @IAmBiotech International Convention and have the opportunity to network with thousands of biotech and pharma leaders. Dr. Kazmi is available for 1-on-1s to discuss our differentiated pipeline.
To partner: https://t.co/LzRfU5Oo29

[Jubilant Therapeutics @JubilantTx]

Jubilant Therapeutics is attending @ASCO Annual Meeting 2023 on June 2-6 in Chicago. Dr. Rastelli, CSO, Dr. Rajagopal, VP & Head of Medicinal Chemistry, and Mr. Krishnan, Associate Director, BD, are excited to connect with our colleagues also working in the oncology field.#ASCO23

[Jubilant Therapeutics @JubilantTx]

Jubilant Therapeutics is attending @IAmBiotech International Convention & is available for partnering. We look forward to discussing our differentiated, orally bioavailable clinical & preclinical programs targeting oncology & autoimmune disease. To partner https://t.co/LzRfU5Oo29

[Jubilant Therapeutics @JubilantTx]

CEO, Dr. Syed Kazmi, is attending #BioEquity 5/14-16 in Dublin and is available for partnering. Our precision #biotech company is compiled of differentiated drug candidates for challenging diseases in #oncology and #autoimmunediseases. Come talk with Dr. Kazmi to learn more.

[Jubilant Therapeutics @JubilantTx]

CEO, Syed Kazmi, Ph.D., spoke with Investment Reports, a @Newsweek provider, about the history of Jubilant Therapeutics, our areas of expertise in the industry, our TIBEO discovery engine helps achieve pipeline goals, & our priorities for the near future.

https://t.co/Wj0vSYYtlG

[Jubilant Therapeutics @JubilantTx]

Dr. Luca Rastelli & other members of the team present data on our brain penetrant small molecule PRMT5 inhibitor JBI-778 for the treatment of cancer @AACR Annual Meeting today. Stop by our poster presentation from 9am-12:30pm EDT in Section 20.

Abstract:https://t.co/fse4PSOt0q

[Jubilant Therapeutics @JubilantTx]

Today our CEO, Syed Kazmi, Ph.D., and CFO, Shyam Pattabiraman, are presenting at @BioNJ_Org BioPartnering Conference from 2:45-4:30pm EDT. If you are attending the conference, please stop by our presentation and learn about Jubilant Therapeutics! #BioNJ #BioP2023

[Jubilant Therapeutics @JubilantTx]

Our CFO, Shyam Pattabiraman is presenting @BioNJ_Org BioPartnering Conference on April 18th and is also available for partnering. Please do catch-up with our presentation between 2:45pm to 4:30pm

Schedule here: https://t.co/nU1SIMS5ia

[Jubilant Therapeutics @JubilantTx]

Publication of research in @SciReports
in collaboration w/ @bch_rc on highly selective, non-competitive, & orally administered PAD4 #inhibitors that demonstrated efficacy in 2 animal models of RA & supports the MOA of inhibition via #invitro studies.

See: https://t.co/YrFmhfPmby

[Jubilant Therapeutics @JubilantTx]

Members of the Jubilant team are attending @AACR this month to present on JBI-778, our novel brain-penetrant small molecule PRMT5 inhibitor for the treatment of cancer. Dr. Sivanandhan, VP & Head, Biology, will lead the presentation.

Abstract: https://t.co/fse4PSOt0q

[Jubilant Therapeutics @JubilantTx]

Today marks 75 years of #WorldHealthDay, a day dedicated to furthering health for all. Jubilant Therapeutics is committed to improving public health through the continued development of our patient-centric research and development.

[Jubilant Therapeutics @JubilantTx]

We present data on our brain penetrant small molecule PRMT5 inhibitor JBI-778 for the treatment of cancer @AACR Annual Meeting in Orlando on 4/19. JBI-778 penetrated the brain in all animal species tested & highly efficacious in orthotopic glioma models.

https://t.co/9YRrBT6Pfe

[Jubilant Therapeutics @JubilantTx]

If you missed the live coverage of our @Baird Biotech Discovery Series fireside chat last week, a replay of the discussion is available on our website. Leaders discussed our lead indication strategy, targeting broad subsets, and the potential of PRMT5.

https://t.co/55Rl0IVJsq

[Jubilant Therapeutics @JubilantTx]

Jubilant Therapeutics’ PAD4 inhibitor, JBI-1044, is showing positive data in preclinical models of #psoriasis, #lungfibrosis including #COVID19 ARDS and has the opportunity for broader application in other autoimmune disorders such as #SLE and #DVT.

#AutoimmuneAwarenessMonth

[Jubilant Therapeutics @JubilantTx]

Members of the Jubilant executive team and board of directors participated in @Baird Biotech Discovery Series Fireside Chat this afternoon. Thank you to our Baird host and moderator for a great discussion about our pipeline of therapeutics!

To listen: https://t.co/55Rl0IVJsq